10-Q Filing

Processa Pharmaceuticals, Inc. CIK: 1533743 Q3 2018

Filing Information

Form Type	10-Q
Accession Number	`0001493152-18-015821`
Period End Date	20180930
Filing Date	20181114
Fiscal Year	2018
Fiscal Period	Q3
XBRL Instance	pcsa-20180930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 48 Cash Flow Statement 72 Stockholders Equity 18

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.07M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.85M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.42M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$62.71K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$94.77K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseCurrent`	$282.32K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseCurrent`	$41.45K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$2.95M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Total Current Assets	`AssetsCurrent`	$2.80M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	35.27M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	38.67M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	35.27M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	38.67M	shares	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$3.25K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$9.58K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$25.82K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$19.49K	USD	Point-in-time
Security deposit	`DepositsAssetsNoncurrent`	$5.54K	USD	Point-in-time
Security deposit	`DepositsAssetsNoncurrent`	$5.54K	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$10.64M	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	-	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$10.64M	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$5.54K	USD	Point-in-time
Total Assets	`Assets`	$13.46M	USD	Point-in-time
Total Assets	`Assets`	$2.98M	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$2.45M	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$227.77K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$15.74K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$35.69K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$50.69K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$80.02K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$436.00	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$100.00	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$64.43K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$367.55K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$691.19K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$2.60M	USD	Point-in-time
Accrued rent liability	`AccruedRentNoncurrent`	-	USD	Point-in-time
Accrued rent liability	`AccruedRentNoncurrent`	$9.96K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	-	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$2.27M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.61M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.96M	USD	Point-in-time
Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at September 30, 2018 and 35,272,626 issued and outstanding at December 31, 2017	`CommonStockValue`	$3.53K	USD	Point-in-time
Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at September 30, 2018 and 35,272,626 issued and outstanding at December 31, 2017	`CommonStockValue`	$3.87K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.23M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$19.32M	USD	Point-in-time
Subscription receivable	`CommonStockSharesSubscriptions`	$-1.80M	USD	Point-in-time
Subscription receivable	`CommonStockSharesSubscriptions`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.86M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.01M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$373.16K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$10.51M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$13.46M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$2.98M	USD	Point-in-time

Income Statement 48 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$611.61K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$772.53K	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$457.63K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.48M	USD	3 Qtrs
General and administrative	`SellingGeneralAndAdministrativeExpense`	$454.59K	USD	3 Qtrs
General and administrative	`SellingGeneralAndAdministrativeExpense`	$451.36K	USD	1 Quarter
General and administrative	`SellingGeneralAndAdministrativeExpense`	$255.22K	USD	1 Quarter
General and administrative	`SellingGeneralAndAdministrativeExpense`	$1.31M	USD	3 Qtrs
Total Operating Expenses	`OperatingExpenses`	$712.85K	USD	1 Quarter
Total Operating Expenses	`OperatingExpenses`	$1.06M	USD	1 Quarter
Total Operating Expenses	`OperatingExpenses`	$1.23M	USD	3 Qtrs
Total Operating Expenses	`OperatingExpenses`	$3.78M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-712.85K	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-3.78M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-1.23M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-1.06M	USD	1 Quarter
Interest expense	`InterestExpense`	$8.32K	USD	1 Quarter
Interest expense	`InterestExpense`	-	USD	1 Quarter
Interest expense	`InterestExpense`	$154.38K	USD	3 Qtrs
Interest expense	`InterestExpense`	-	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$6.46K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.28K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$4.67K	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$10.16K	USD	3 Qtrs
Total Other Income (Expense)	`OtherOperatingIncomeExpenseNet`	$-1.87K	USD	1 Quarter
Total Other Income (Expense)	`OtherOperatingIncomeExpenseNet`	$-144.21K	USD	3 Qtrs
Total Other Income (Expense)	`OtherOperatingIncomeExpenseNet`	$1.28K	USD	1 Quarter
Total Other Income (Expense)	`OtherOperatingIncomeExpenseNet`	$4.67K	USD	3 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-711.57K	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.06M	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.22M	USD	3 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.93M	USD	3 Qtrs
Income Tax Benefit	`IncomeTaxExpenseBenefit`	-	USD	3 Qtrs
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-771.33K	USD	3 Qtrs
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-212.01K	USD	1 Quarter
Income Tax Benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-711.57K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.22M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-3.16M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-852.82K	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.09	USD	3 Qtrs
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	38.67M	shares	1 Quarter
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	31.75M	shares	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	31.75M	shares	1 Quarter
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	36.87M	shares	3 Qtrs

Cash Flow Statement 72 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	3 Qtrs
Common stock, shares transferred	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	31.75M	shares	Point-in-time
Net Loss	`NetIncomeLoss`	$-711.57K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-1.22M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-3.16M	USD	3 Qtrs
Conversion of senior convertible debt, value	`ConversionOfSeniorConvertibleDebtValue`	$2.35M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-852.82K	USD	1 Quarter
Accrued interest converted into shares of common stock	`AccruedInterestConvertedIntoSharesOfCommonStock`	1.21M	shares	3 Qtrs
Depreciation	`Depreciation`	$6.33K	USD	3 Qtrs
Depreciation	`Depreciation`	$-2.68K	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$200.26K	USD	1 Quarter
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	-	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$422.81K	USD	3 Qtrs
Deferred income tax (benefit) expense	`DeferredIncomeTaxExpenseBenefit`	$-771.33K	USD	3 Qtrs
Deferred income tax (benefit) expense	`DeferredIncomeTaxExpenseBenefit`	-	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$64.84K	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	-	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$50.53K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	-	USD	3 Qtrs
Prepaid expenses and other	`IncreaseDecreaseInPrepaidExpense`	$-2.06K	USD	3 Qtrs
Prepaid expenses and other	`IncreaseDecreaseInPrepaidExpense`	$240.87K	USD	3 Qtrs
Vendor deposit	`IncreaseDecreaseInDeposits`	$227.66K	USD	3 Qtrs
Vendor deposit	`IncreaseDecreaseInDeposits`	-	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	-	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$89.52K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$29.89K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$29.33K	USD	3 Qtrs
Due from related parties	`IncreaseDecreaseInDueFromRelatedParties`	$32.39K	USD	3 Qtrs
Due from related parties	`IncreaseDecreaseInDueFromRelatedParties`	$35.32K	USD	3 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$293.16K	USD	3 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$22.02K	USD	3 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-978.82K	USD	3 Qtrs
Net Cash Used In Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.24M	USD	3 Qtrs
Proceeds from certificates of deposit	`ProceedsFromOtherDeposits`	$1.02M	USD	3 Qtrs
Proceeds from certificates of deposit	`ProceedsFromOtherDeposits`	-	USD	3 Qtrs
Purchase of software license	`PaymentsToAcquireSoftware`	-	USD	3 Qtrs
Purchase of software license	`PaymentsToAcquireSoftware`	$20.50K	USD	3 Qtrs
Acquisition of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	3 Qtrs
Acquisition of intangible asset	`PaymentsToAcquireIntangibleAssets`	$1.78K	USD	3 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$1.02M	USD	3 Qtrs
Net Cash Used In Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-22.28K	USD	3 Qtrs
Net proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Net proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$2.97M	USD	3 Qtrs
Payment of debt issuance costs	`PaymentsOfDebtIssuanceCosts`	$75.00K	USD	3 Qtrs
Payment of debt issuance costs	`PaymentsOfDebtIssuanceCosts`	-	USD	3 Qtrs
Transaction costs incurred in connection with the conversion of senior convertible notes	`ProceedsFromUnsecuredNotesPayable`	-	USD	3 Qtrs
Transaction costs incurred in connection with the conversion of senior convertible notes	`ProceedsFromUnsecuredNotesPayable`	$-4.74K	USD	3 Qtrs
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	-	USD	3 Qtrs
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	$-117.34K	USD	3 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$2.84M	USD	3 Qtrs
Net Cash Provided By Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-75.00K	USD	3 Qtrs
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-34.53K	USD	3 Qtrs
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-423.21K	USD	3 Qtrs
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$1.07M	USD	Point-in-time
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$2.85M	USD	Point-in-time
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$2.42M	USD	Point-in-time
CASH AND CASH EQUIVALENTS END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$1.07M	USD	Point-in-time
CASH AND CASH EQUIVALENTS END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$1.04M	USD	Point-in-time
CASH AND CASH EQUIVALENTS END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$2.85M	USD	Point-in-time
CASH AND CASH EQUIVALENTS END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$2.42M	USD	Point-in-time
Recognize exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	-	USD	3 Qtrs
Recognize exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	$-11.04M	USD	3 Qtrs
Recognize deferred tax liability for basis difference for intangible asset	`RecognizationOfDeferredTaxLiability`	$3.04M	USD	3 Qtrs
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa owned by Promet to CoNCERT	`PaymentOfAdditionalPaidInCapitalForConsideration`	$8.00M	USD	3 Qtrs
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa owned by Promet to CoNCERT	`PaymentOfAdditionalPaidInCapitalForConsideration`	-	USD	3 Qtrs
Cash paid for intangible asset acquired from CoNCERT	`CashPaidForIntangibleAssetAcquired`	-	USD	3 Qtrs
Cash paid for intangible asset acquired from CoNCERT	`CashPaidForIntangibleAssetAcquired`	-	USD	3 Qtrs
Conversion of $2,350,000 of Senior Convertible Debt and related accrued interest into 1,206,245 shares of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	-	USD	3 Qtrs
Conversion of $2,350,000 of Senior Convertible Debt and related accrued interest into 1,206,245 shares of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$2.40M	USD	3 Qtrs
Common stock and stock purchase warrants issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsIssuedInConnectionWithClinicalTrialFundingCommitment`	$1.80M	USD	3 Qtrs
Common stock and stock purchase warrants issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsIssuedInConnectionWithClinicalTrialFundingCommitment`	-	USD	3 Qtrs

Stockholders Equity 18 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares exchanged	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	2.09M	shares	3 Qtrs
Common stock, shares exchanged	`BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued`	31.75M	shares	Point-in-time
Conversion of stock, costs	`ConversionOfStockNetOfCosts`	$4.74K	USD	3 Qtrs
Issuance of common stock units for cash, cost	`PaymentsOfStockIssuanceCosts`	$218.42K	USD	3 Qtrs
Issuance of common stock units for a future research funding commitment, cost	`IssuanceOfCommonStockUnitsForFutureResearchFundingCommitmentCost`	$117.34K	USD	3 Qtrs
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$10.51M	USD	Point-in-time
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 common shares of Processa owned by Promet	`FairValueOfExclusiveLicenseIntangibleAssetAcquired`	8.00M	shares	3 Qtrs
Conversion of Senior convertible notes for common stock and stock purchase warrants, net of costs of $4,742	`StockIssuedDuringPeriodValueConversionOfUnits`	$2.39M	USD	3 Qtrs
Issuance of common stock units for cash, net of costs of $218,422	`StockIssuedDuringPeriodValueNewIssues`	$2.97M	USD	3 Qtrs
Issuance of common stock units for a clinical trial funding commitment, net of costs of $117,339	`StockIssuedDuringPeriodValueOther`	$-117.34K	USD	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$50.53K	USD	3 Qtrs
Net loss for the nine months ended September 30, 2018	`NetIncomeLoss`	$-711.57K	USD	1 Quarter
Net loss for the nine months ended September 30, 2018	`NetIncomeLoss`	$-1.22M	USD	3 Qtrs
Net loss for the nine months ended September 30, 2018	`NetIncomeLoss`	$-3.16M	USD	3 Qtrs
Net loss for the nine months ended September 30, 2018	`NetIncomeLoss`	$-852.82K	USD	1 Quarter
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$10.51M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.